“Can someone help me understand please. I'm wond
Post# of 148187
The recommendation to review 42 day data at 75% was made by the DSMC (or the DSMB for those Jlangs of the board) at the 50% interim analysis. There’s speculation as to why the recommendation was made, but there’s generally one main theme to the discussion: mortality may be higher between the 28-42 day mark and if so, a primary endpoint of 42 days could be better than 28 day mortality. Now, some investros argue that recommendation was made in order to end the trial early at the 75%. Other investors argue that recommendation was made because 42 day mortality at full enrollment could be better than 28 day mortality. Either way, the 42 day recommendation was made for the 75% interim analysis and not as a change to a primary or secondary endpoint.